Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Erasca Inc (ERAS)
Assess today's live Erasca Inc (ERAS) share price, performance and insights using our live NASDAQ: ERAS stock exchange data.
Analyse the historical data and Erasca Inc share price performance charts on this page. Our technical summary section provides analysis on Erasca share price buy/sell indicators using real-time data (or discuss the Erasca (ERAS) stock price today with other investors in the Erasca NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ERAS share price (ISIN: US29479A1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Erasca Inc Share Price Today?
The Erasca share price today is 13.645.
What Is the Stock Symbol for Erasca Inc
The stock symbol (or 'ticker') for Erasca Inc is "ERAS."
What Stock Exchange Does Erasca Inc Trade On?
Erasca Inc is listed and trades on the NASDAQ stock exchange.
Is Erasca Inc a Good Stock to Buy?
Determining whether Erasca Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Erasca Inc share price performance charts on this page. Our technical summary section provides analysis on Erasca share price buy/sell indicators using real-time data (or discuss the Erasca (ERAS) stock price today with other investors in the Erasca NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ERAS share price (ISIN: US29479A1088) to enhance your trading decisions with our free investment tools and resources.
What Is the Erasca Inc Share Price Today?
The Erasca share price today is 13.645.
What Is the Stock Symbol for Erasca Inc
The stock symbol (or 'ticker') for Erasca Inc is "ERAS."
What Stock Exchange Does Erasca Inc Trade On?
Erasca Inc is listed and trades on the NASDAQ stock exchange.
Is Erasca Inc a Good Stock to Buy?
Determining whether Erasca Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
NASDAQ
Currency in USD
13.645
+0.145(+1.07%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.360
13.850
52 wk Range
1.010
16.405
ERAS is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
13.36013.850
52 wk Range
1.01016.405
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ERAS Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
16.800
Upside
+23.12%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Suffers from weak gross profit margins
- Form 144 Erasca For: 16 March
- Investing.com
- Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Form 144 Erasca For: 16 March
- Investing.com
- Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Erasca receives Investment Bank Analyst Rating Update
- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Strong Buy
Moving Averages
Neutral
Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 biparatopic antibody (bpAb) for the treatment of EGFR and RAS/MAPK solid tumors. It has license agreement with Guangzhou Joyo Pharmatech Co., Ltd to develop, manufacture, and commercialize certain pan-RAS inhibitors; Medshine Discovery Inc. to develop, manufacture, and commercialize certain pan-KRAS inhibitors; Novartis Pharma AG to develop, manufacture, use, and commercialize naporafenib; NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds; and Asana BioSciences, LLC to develop and commercialize ERAS-007 and certain other related compounds. The company has a clinical trial collaboration and supply agreement with Tango Therapeutics, Inc. for the evaluation of ERAS-0015. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.
Compare ERAS to Peers and Sector
Metrics to compare | ERAS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipERASPeersSector | |
|---|---|---|---|---|
P/E Ratio | −33.7x | −4.0x | −0.5x | |
PEG Ratio | −0.92 | −0.15 | 0.00 | |
Price/Book | 12.9x | 3.1x | 2.6x | |
Price / LTM Sales | - | 8.4x | 3.2x | |
Upside (Analyst Target) | 44.4% | 72.7% | 53.4% | |
Fair Value Upside | Unlock | 16.9% | 7.7% | Unlock |
Analyst Ratings
8 Buy
1 Hold
1 Sell
Ratings:
10 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 16.800
(+23.12% Upside)
Earnings
Latest Release
12/03/2026
EPS / Forecast
-0.10 / -0.11
Revenue / Forecast
-- / --
People Also Watch
FAQ
What Is the Erasca (ERAS) Share Price Today?
The Erasca stock price today is 13.645 USD.
What Stock Exchange Does Erasca (ERAS) Trade On?
Erasca is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Erasca?
The stock symbol (also called a 'ticker') for Erasca is "ERAS."
What Is the Current Erasca Market Cap?
As of today, Erasca market cap is 4.250B USD.
What Is Erasca's (ERAS) Earnings Per Share (TTM)?
The Erasca EPS is currently -0.439 (Trailing Twelve Months).
When Is the Next Erasca Earnings Date?
Erasca's next earnings report will be released on 07/05/2026.
Is ERAS a Buy or Sell From a Technical Analyst Perspective?
Based on today's Erasca moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Erasca Stock Split?
Erasca has split 0 times. (See the ERAS stock split history page for full effective split date and price information.)
How Many Employees Does Erasca Have?
Erasca has 103 employees.
What is the current trading status of Erasca (ERAS)?
As of 19/03/2026, Erasca (ERAS) is trading at a price of 13.645 USD, with a previous close of 13.500 USD. The stock has fluctuated within a day range of 13.360 USD to 13.850 USD, while its 52-week range spans from 1.010 USD to 16.405 USD.
What Is Erasca (ERAS) Price Target According to Analysts?
The average 12-month price target for Erasca is 16.800 USD, with a high estimate of 25 USD and a low estimate of 2 USD. 8 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +23.12% Upside potential.
What Is the ERAS Premarket Price?
ERAS's last pre-market stock price is 13.630 USD. The pre-market share volume is 13,320.000, and the stock has decreased by 0.130, or 0.960%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.